We are live on ! Find out more
PASG icon

Passage Bio

75 hedge funds and large institutions have $38.1M invested in Passage Bio in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 31 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

0.27% less ownership

Funds ownership: 3.88%3.62% (-0.27%)

12% less funds holding

Funds holding: 8575 (-10)

51% less capital invested

Capital invested by funds: $78.4M → $38.1M (-$40.3M)

52% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 31

53% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 19

Holders
75
Holders Change
-10
Holders Change %
-11.76%
% of All Funds
1.29%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
9
Increased
15
Reduced
31
Closed
19
Calls
$62K
Puts
Net Calls
+$62K
Net Calls Change
+$61K

PASG Hedge Fund Activity: Q3 2022 in Review

75 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q3 2022, worth a combined $38.1M — down 51% from $78.4M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of PASG and 9 opened new positions — a net loss of 10 holders — while 31 trimmed existing stakes and 15 added.

The largest buyer was Lynx1 Capital Management, adding an estimated $4.59M. The largest seller was Woodline Partners, cutting an estimated $2.69M.

  • 75 institutional investors held Passage Bio (PASG) as of Q3 2022, down from 85 in Q2 2022.
  • Funds reported $38.1M of Passage Bio stock for Q3 2022, down 51% quarter-over-quarter.
  • 9 funds opened new Passage Bio positions in Q3 2022 and 19 closed out, a net change of -10 holders.
  • The largest Passage Bio buyer in Q3 2022 was Lynx1 Capital Management, an estimated $4.59M added.
  • The largest Passage Bio seller in Q3 2022 was Woodline Partners, an estimated $2.69M sold.

Based on aggregated 13F filings for Q3 2022.